Recurrent ovarian cancer: bevacizumab-sorafenib combo misses mark

  • Lee J et al.
  • Gynecol Oncol
  • 1 Aug 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Bevacizumab plus sorafenib fails to achieve clinical benefit threshold in patients with heavily pretreated ovarian cancer.
  • Clinical activity was observed in bevacizumab-naive patients.
  • Baseline low plasma IL-8 levels were associated with clinical benefit.

Why this matters

  • Patients with recurrent ovarian cancer have poor prognosis.

Study design

  • Phase 2 study of 54 heavily treated patients (41 bevacizumab-naive and 13 bevacizumab-prior) with ovarian cancer treated with bevacizumab+sorafenib.
  • Funding: National Cancer Institute.

Key results

  • In 35 evaluable bevacizumab-naive patients:
    • Overall clinical benefit rate was 77%.
    • 9 patients achieved partial responses, and 18 had stable disease ≥4 months.
    • The overall median PFS was 5.5 (95% CI, 4.0-6.8) months.
  • In the bevacizumab-prior group:
    • No responses were observed.
    • 54% of patients had SD ≥4 months.
    • Median PFS was 4.0 (95% CI, 2.0-6.4) months.
  • All grade 3/4 toxicities were seen in bevacizumab-naive patients.
    • The most common treatment-related grade 3/4 adverse events were hypertension (31%) and venous thrombosis or pulmonary embolism (9%).
  • Baseline low IL-8 concentration was associated with PFS ≥4 months (median, 12.88 vs 21.26 ng/mL; P=.031).

Limitations

  • Open-label, single-group.